Apollon Wealth Management LLC Has $2.47 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Apollon Wealth Management LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 25.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 12,515 shares of the company’s stock after purchasing an additional 2,541 shares during the period. Apollon Wealth Management LLC’s holdings in Zoetis were worth $2,470,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC boosted its stake in shares of Zoetis by 7.4% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after buying an additional 6,457 shares during the period. Peak Financial Advisors LLC acquired a new position in Zoetis during the fourth quarter worth about $2,776,000. Ninety One UK Ltd lifted its holdings in shares of Zoetis by 13.1% in the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after purchasing an additional 17,976 shares during the last quarter. Finally, Advisor Partners II LLC increased its position in Zoetis by 4.0% during the 3rd quarter. Advisor Partners II LLC now owns 24,068 shares of the company’s stock worth $4,187,000 after purchasing an additional 922 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group cut their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis presently has an average rating of “Buy” and an average target price of $212.38.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 2,209 shares of company stock worth $371,293 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded up $2.50 during trading hours on Tuesday, reaching $168.45. 3,318,087 shares of the stock traded hands, compared to its average volume of 3,179,154. The company’s 50-day moving average price is $168.25 and its two-hundred day moving average price is $178.92. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a market cap of $76.86 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.31 EPS. On average, analysts anticipate that Zoetis Inc. will post 5.77 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.